Literature DB >> 2387245

Tumor necrosis factor acutely increases plasma levels of very low density lipoproteins of normal size and composition.

R M Krauss1, C Grunfeld, W T Doerrler, K R Feingold.   

Abstract

Tumor necrosis factor (TNF) has been proposed to mediate the hypertriglyceridemic response to infection by either increasing hepatic lipid synthesis or decreasing clearance of triglyceride-rich particles through inhibition of lipoprotein lipase. We demonstrate that within 90 min of administration of recombinant human TNF alpha to rats there is a rapid increase in plasma levels of very low density lipoproteins (VLDL) of normal ultracentrifugal flotation rate, apoprotein and lipid composition, and particle size, as assessed by nondenaturing gradient gel electrophoresis. Clearance of radioiodinated VLDL 90 min after TNF administration did not differ from that in control animals, consistent with other observations that increases in plasma triglyceride concentrations after TNF precede detectable reductions in tissue lipoprotein lipase activity. Between 90 min and 16 h after TNF, VLDL levels decline, and there are increases in intermediate (IDL) and low (LDL) density lipoproteins consistent with lipolytic processing of VLDL, although the findings are also compatible with direct secretion of IDL and LDL subspecies. By 16 h, there is a 50% increase in protein mass of LDL of normal composition and subspecies distribution, as assessed by nondenaturing gradient gel electrophoresis. These data suggest that the initial locus of TNF's metabolic effects is the liver, and the resulting increases in secretion and metabolic processing of VLDL may represent an early manifestation of the acute phase response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387245     DOI: 10.1210/endo-127-3-1016

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Escherichia coli sepsis increases hepatic apolipoprotein B secretion by inhibiting degradation.

Authors:  H W Phetteplace; N Sedkova; K I Hirano; N O Davidson; S P Lanza-Jacoby
Journal:  Lipids       Date:  2000-10       Impact factor: 1.880

2.  The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle.

Authors:  F Benigni; T Atsumi; T Calandra; C Metz; B Echtenacher; T Peng; R Bucala
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

3.  Effect of tumor necrosis factor-alpha on triglyceride and phospholipid content and fatty acid composition of liver and carcass in rats.

Authors:  N Raina; J Matsui; S C Cunnane; K N Jeejeebhoy
Journal:  Lipids       Date:  1995-08       Impact factor: 1.880

4.  Metabolic effects of tumour necrosis factor-alpha on rat brown adipose tissue.

Authors:  J López-Soriano; J M Argilés; F J López-Soriano
Journal:  Mol Cell Biochem       Date:  1995-02-23       Impact factor: 3.396

Review 5.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

6.  Responses of adipose and muscle lipoprotein lipase to chronic infection and subsequent acute lipopolysaccharide challenge.

Authors:  Frédéric Picard; Denis Arsenijevic; Denis Richard; Yves Deshaies
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

7.  Role for circulating lipoproteins in protection from endotoxin toxicity.

Authors:  K R Feingold; J L Funk; A H Moser; J K Shigenaga; J H Rapp; C Grunfeld
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Upregulation of low density lipoprotein receptor activity by tumor necrosis factor, a process independent of tumor necrosis factor-induced lipid synthesis and secretion.

Authors:  W Liao; C H Florén
Journal:  Lipids       Date:  1994-10       Impact factor: 1.880

Review 9.  Inflammation and Cardiovascular Disease: The Future.

Authors:  Natalie Arnold; Katharina Lechner; Christoph Waldeyer; Michael D Shapiro; Wolfgang Koenig
Journal:  Eur Cardiol       Date:  2021-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.